Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
Pharmaceuticals (Basel)
; 15(8)2022 Aug 22.
Article
en En
| MEDLINE
| ID: mdl-36015181
ABSTRACT
BACKGROUND:
Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of â¼3 years. Several risk factors have been identified, such as age, genetic predisposition, tobacco exposure, and gastro-oesophageal reflux disease (GERD). Prevalence of GERD in IPF is high and may affect 87% of patients, of whom only half (47%) report symptoms.Objective:
The aim of this study is to review current evidence regarding the correlation between GERD and IPF and to evaluate the current studies regarding treatments for GERD-IPF.Methods:
A review to identify research papers documenting an association between GERD and IPF was performed.Results:
We identified several studies that have confirmed the association between GERD and IPF, with an increased acid exposure, risk of gastric aspiration and bile acids levels in these patients. Few studies focused their attention on GERD treatment, showing how antiacid therapy was not able to change IPF evolution.Conclusions:
This review investigating the correlation between GERD and IPF has confirmed the hypothesized association. However, further large prospective studies are needed to corroborate and elucidate these findings with a focus on preventative and treatment strategies.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Pharmaceuticals (Basel)
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia